Liver-Targeted DNP Derivatives for NAFLD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for non-alcoholic fatty liver disease (NAFLD) and related conditions lack effective treatments that safely increase mitochondrial activity without causing systemic toxicities like hypothermia, which were associated with earlier mitochondrial uncoupling agents.
Innovation Solution
Development of liver-targeted derivatives of 2,4-dinitrophenol (DNP) that promote increased mitochondrial activity specifically in the liver, avoiding systemic toxicities by preferentially metabolizing in the liver and reducing hypertriglyceridemia, NAFLD, and insulin resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mitochondrial uncoupling agents like DNP are used to increase mitochondrial activity and treat NAFLD, then metabolic effects are improved, but systemic toxicities such as hypothermia and fatal hyperthermia occur
Solution Approach 1:
The patent applies local quality by designing liver-targeted DNP derivatives that selectively accumulate in liver tissue through active transport mechanisms (OATP1B3, OCT1, NTCP) while being excluded from other tissues. This is achieved by attaching liver-specific targeting moieties to the DNP core structure, enabling the drug to exert metabolic effects locally in the liver without causing systemic toxicities like hypothermia or fatal hyperthermia that occurred with systemic DNP administration.
2Use of energy by moving object
If DNP is administered to promote weight loss and treat metabolic disorders, then energy expenditure increases, but fatal hyperthermia and other adverse effects occur
Solution Approach 1:
The patent uses liver-specific transport proteins (OATP1B3, OCT1, NTCP) as intermediaries to deliver DNP derivatives selectively to liver tissue. These transporters act as mediators that facilitate the uptake of the drug into hepatocytes while preventing its distribution to other tissues. This intermediary mechanism enables controlled energy expenditure in the liver for treating NAFLD and hypertriglyceridemia without causing the uncontrolled hyperthermia and adverse effects associated with systemic DNP administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The liver-targeted DNP derivatives effectively decrease hypertriglyceridemia, fatty liver, and insulin resistance without causing systemic toxicities, providing a safe and novel approach for treating NAFLD and related metabolic disorders.
Implementation Method 1
2,4-dinitrophenol (DNP), a protonophore that shuttles protons across the mitochondrial membrane, dissipating the mitochondrial proton gradient and promoting heat dissipation of the energy derived from mitochondrial substrate oxidation
Data Source
AI summary
The present invention includes DNP derivatives that are useful for preventing or treating a metabolic disease or disorder in a subject in need thereof. In certain embodiments, the subject is further administered at least one additional therapeutic agent.